-+ 0.00%
-+ 0.00%
-+ 0.00%

Innovent to present IBI363 clinical data at ASCO annual meeting

PUBT·04/22/2026 00:00:43
Listen to the news
Innovent to present IBI363 clinical data at ASCO annual meeting
  • Innovent will present new clinical data on IBI363, its PD-1/IL-2α-biased bispecific fusion protein, at 2026 ASCO Annual Meeting in Chicago on May 29 to June 2, 2026.
  • Data include first-line advanced NSCLC results for IBI363 with chemotherapy on May 31, 2026.
  • Updated phase 1 results in immunotherapy-resistant NSCLC are scheduled for May 30, 2026.
  • Company also plans multiple presentations on TYVYT (sintilimab) across tumor types during meeting, including a phase III study in advanced hepatocellular carcinoma on May 30, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN39580) on April 22, 2026, and is solely responsible for the information contained therein.